SCHEMBL5880885

SCHEMBL5880885

COc1ccc(CCC2(C3CCCC3)CC(=O)C(C(=O)Cc3cccnc3)C(=O)O2)c(OC)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.39
POLB P06746 1/20 0.39
KMT2A Q03164 2/20 0.37
TSHR P16473 1/20 0.37
IDO1 P14902 2/20 0.37
CYP1A2 P05177 2/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2C9 P11712 2/20 0.37
CYP2C19 P33261 2/20 0.37
GAA P10253 2/20 0.37
MEN1 O00255 1/20 0.37
MAPT P10636 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
HPGD P15428 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
CYP2D6 P10635 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36
HTT P42858 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5880797 0.91 ALDH1A1 (0.41) ALDH1A1POLBKMT2ATSHRGAA
SCHEMBL5880856 0.89 MAPT (0.38) ALDH1A1POLBKMT2AIDO1GAA
SCHEMBL5880893 0.83 KMT2A (0.42) ALDH1A1POLBKMT2ATSHRMEN1
SCHEMBL5880936 0.81 MEN1 (0.39) ALDH1A1POLBKMT2ATSHRMEN1
SCHEMBL5880782 0.80 NPC1 (0.38) ALDH1A1KMT2ATSHRIDO1GAA
SCHEMBL5880800 0.80 KMT2A (0.39) ALDH1A1POLBKMT2ATSHRCYP1A2
SCHEMBL5880886 0.79 ALDH1A1 (0.39) ALDH1A1POLBKMT2AMEN1MAPT
SCHEMBL5881026 0.77 CA2 (0.36) ALDH1A1KMT2ATSHRGAAMEN1
SCHEMBL5880836 0.75 KMT2A (0.37) ALDH1A1POLBKMT2ATSHRMEN1
SCHEMBL5880874 0.74 MEN1 (0.39) ALDH1A1KMT2ATSHRMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7115658-B2 Inhibitors of hepatitis C virus RNA-dependent RNA polymerase AGOURON PHARMACEUTICALS, INC. (US) 2006-10-03 US disclosed
US-20040023958-A1 Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same AGOURON PHARMACEUTICALS, INC. 2004-02-05 US disclosed
WO-2003095441-A1 INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME PFIZER INC. (US) 2003-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040023958-A1 Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same POLRMT, RNGTT, RNASE1 ALDH1A1 729/4885POLB 30/4885KMT2A 3031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.